Sarah B. Noonberg

Chief Medical Officer, PROTHENA CORP PUBLIC LTD CO.

Companies

Metagenomi Therapeutics, Inc.Chief Medical Officer Feb 8, 2024 to now¹
Neurogene Inc.Board member Aug 12, 2019 to now²
Marinus Pharmaceuticals (United States)Board member May 17, 2023 to Jun 20, 2024³
Protagonist Therapeutics, IncBoard member Dec 19, 2017 to Jan 18, 2023⁴
PROTHENA CORP PUBLIC LTD COChief Medical Officer May 18, 2017 to May 18, 2017⁵

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Metagenomi Therapeutics, Inc. MGX109,135 shares⁶$88.9K at $0.81Jun 6, 2025
Marinus Pharmaceuticals (United States)14,100 shares⁷Jun 18, 2024

As of each latest filing. The line shows shares held over time.

Recent filings

Jun 6, 2025Sold 5,239 shares at $1.75 of Metagenomi Therapeutics, Inc.⁶
Apr 1, 2025Granted 14,000 shares of Metagenomi Therapeutics, Inc.⁸
Jun 18, 2024Granted 2,300 shares of Marinus Pharmaceuticals (United States)⁷
Apr 1, 2024Granted 57,763 shares of Metagenomi Therapeutics, Inc.⁹
Jan 18, 2024Granted 4,600 shares of Marinus Pharmaceuticals (United States)¹⁰
May 16, 2023Granted 7,200 shares of Marinus Pharmaceuticals (United States)¹¹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARMetagenomi Therapeutics, Inc., Chief Medical Officer
2
SEC EDGARNeurogene Inc., Board member
3
SEC EDGARMarinus Pharmaceuticals (United States), Board member
4
SEC EDGARProtagonist Therapeutics, Inc, Board member
5
SEC EDGARPROTHENA CORP PUBLIC LTD CO, Chief Medical Officer
6
SEC EDGARMetagenomi Therapeutics, Inc. shares after the filing of Jun 6, 2025
7
SEC EDGARMarinus Pharmaceuticals (United States) shares after the filing of Jun 18, 2024
8
SEC EDGARForm 4 filed Apr 3, 2025
9
SEC EDGARForm 4 filed Apr 3, 2024
10
SEC EDGARForm 4 filed Jan 19, 2024
11
SEC EDGARForm 4 filed May 17, 2023